Oxygenta Pharmaceutical (524636) Q3 24/25 earnings summary

Executive summary

• Board approved unaudited financial results for the quarter ended December 31, 2024, following Audit Committee recommendation and statutory auditor review.

• Meeting for approval held on February 14, 2025.

Financial highlights

• Total revenue for Q3 FY25 was ₹3,369.43 lakhs, up from ₹917.83 lakhs in Q3 FY24.

• Loss before tax for Q3 FY25 was ₹496.19 lakhs, compared to a loss of ₹354.61 lakhs in Q3 FY24.

• Net loss for Q3 FY25 stood at ₹392.83 lakhs, versus ₹377.64 lakhs in Q3 FY24.

• Basic and diluted EPS for Q3 FY25 were both negative at (1.07) and (1.09) respectively.

Key financial ratios and metrics

• Gross margin and EBITDA not explicitly stated; however, significant increase in revenue did not translate to profitability.

• Paid-up equity share capital increased to ₹3,698.35 lakhs as of December 31, 2024.